Clinical Trials
9 trialsNCT05773274 2026-05-26
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT02315625 2020-09-09
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02402062 2020-07-27
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT01215578 2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT01121562 2014-06-30
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 2 Completed
NCT00434109 2012-09-14
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00056693 2008-07-21
Treatment With SU11248 in Patients With Neuroendocrine Tumors
Pfizer
Phase 2 Completed